ONCY Relative Valuation
ONCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ONCY is overvalued; if below, it's undervalued.
Historical Valuation
Oncolytics Biotech Inc (ONCY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.72. The fair price of Oncolytics Biotech Inc (ONCY) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.91
Fair
-4.44
PE
1Y
3Y
5Y
Trailing
Forward
-2.55
EV/EBITDA
Oncolytics Biotech Inc. (ONCY) has a current EV/EBITDA of -2.55. The 5-year average EV/EBITDA is -2.71. The thresholds are as follows: Strongly Undervalued below -5.75, Undervalued between -5.75 and -4.23, Fairly Valued between -1.20 and -4.23, Overvalued between -1.20 and 0.32, and Strongly Overvalued above 0.32. The current Forward EV/EBITDA of -2.55 falls within the Historic Trend Line -Fairly Valued range.
-2.96
EV/EBIT
Oncolytics Biotech Inc. (ONCY) has a current EV/EBIT of -2.96. The 5-year average EV/EBIT is -2.89. The thresholds are as follows: Strongly Undervalued below -6.05, Undervalued between -6.05 and -4.47, Fairly Valued between -1.31 and -4.47, Overvalued between -1.31 and 0.26, and Strongly Overvalued above 0.26. The current Forward EV/EBIT of -2.96 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Oncolytics Biotech Inc. (ONCY) has a current PS of 0.00. The 5-year average PS is 21.67. The thresholds are as follows: Strongly Undervalued below -60.24, Undervalued between -60.24 and -19.28, Fairly Valued between 62.63 and -19.28, Overvalued between 62.63 and 103.58, and Strongly Overvalued above 103.58. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.27
P/OCF
Oncolytics Biotech Inc. (ONCY) has a current P/OCF of -2.27. The 5-year average P/OCF is -3.89. The thresholds are as follows: Strongly Undervalued below -7.85, Undervalued between -7.85 and -5.87, Fairly Valued between -1.91 and -5.87, Overvalued between -1.91 and 0.07, and Strongly Overvalued above 0.07. The current Forward P/OCF of -2.27 falls within the Historic Trend Line -Fairly Valued range.
-1.68
P/FCF
Oncolytics Biotech Inc. (ONCY) has a current P/FCF of -1.68. The 5-year average P/FCF is -3.09. The thresholds are as follows: Strongly Undervalued below -6.24, Undervalued between -6.24 and -4.67, Fairly Valued between -1.52 and -4.67, Overvalued between -1.52 and 0.05, and Strongly Overvalued above 0.05. The current Forward P/FCF of -1.68 falls within the Historic Trend Line -Fairly Valued range.
Oncolytics Biotech Inc (ONCY) has a current Price-to-Book (P/B) ratio of 1140.40. Compared to its 3-year average P/B ratio of 96.19 , the current P/B ratio is approximately 1085.63% higher. Relative to its 5-year average P/B ratio of 59.15, the current P/B ratio is about 1827.94% higher. Oncolytics Biotech Inc (ONCY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.85%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.20% , the current FCF yield is about -100.00% lower.
1234.33
P/B
Median3y
96.19
Median5y
59.15
-19.72
FCF Yield
Median3y
-22.85
Median5y
-21.20
Competitors Valuation Multiple
The average P/S ratio for ONCY's competitors is 0.00, providing a benchmark for relative valuation. Oncolytics Biotech Inc Corp (ONCY) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ONCY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ONCY in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Oncolytics Biotech Inc (ONCY) currently overvalued or undervalued?
What is Oncolytics Biotech Inc (ONCY) fair value?
How does ONCY's valuation metrics compare to the industry average?
What is the current P/B ratio for Oncolytics Biotech Inc (ONCY) as of Dec 05 2025?
What is the current FCF Yield for Oncolytics Biotech Inc (ONCY) as of Dec 05 2025?
What is the current Forward P/E ratio for Oncolytics Biotech Inc (ONCY) as of Dec 05 2025?